Countdown toNOPAIN Act:

87

Days

ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.

Pacira is focused on developing and delivering non-opioid pain management and regenerative health solutions to advance and improve outcomes for health care practitioners and both pediatric patients aged six and older and adults.

Learn more about our therapies by selecting a product below.

productsProducts

EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.*

The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal.

Proprietary multivesicular liposome (pMVL) technology encapsulates drugs, preserving their molecular structure, and releases them over a desired period of time.

ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is the first and only approved treatment for osteoarthritis (OA) knee pain utilizing extended-release microsphere technology.

Pacira is expanding the clinical evidence for EXPAREL through trials across several surgical specialties. Please click here for a list of Pacira-sponsored trials that are currently ongoing.

*The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.